Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 2968462, 14 pages
http://dx.doi.org/10.1155/2016/2968462
Research Article

Epigallocatechin-3-gallate Attenuates Renal Damage by Suppressing Oxidative Stress in Diabetic db/db Mice

1Division of Nephrology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gong Wei Road, Shanghai, China
2Division of Nephrology, Shanghai No. 9 People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3The Institutes of Biomedical Sciences (IBS), Fudan University, Shanghai, China
4Hemodialysis Center, Bao Shan Branch of No. 1 People’s Hospital, Shanghai Jiao Tong University, Shanghai, China

Received 22 May 2016; Revised 14 July 2016; Accepted 9 August 2016

Academic Editor: Claudio Cabello-Verrugio

Copyright © 2016 Xiu Hong Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Epigallocatechin-3-gallate (EGCG), extracted from green tea, has been shown to have antioxidative activity. In the present study, we evaluated the effect of EGCG on the kidney function in db/db mice and also tried to investigate the underlying mechanism of the renoprotective effects of EGCG in both animals and cells. EGCG treatment could decrease the level of urinary protein, 8-iso-PGF2a, and Ang II. Moreover, EGCG could also change the level of several parameters associated with oxidative stress. In addition, the protein expression levels of AT-1R, p22-phox, p47-phox, p-ERK1/2, p-p38 MAPK, TGF-β1, and α-SMA in diabetic db/db mice were upregulated, and all of these symptoms were downregulated with the treatment of EGCG at 50 and 100 mg/kg/d. Furthermore, the pathological changes were ameliorated in db/db mice after EGCG treatment. HK-2 cell-based experiments indicated that EGCG could inhibit the expression of MAPK pathways, which is the downstream effector of Ang II mediated oxidative stress. All these results indicated that EGCG treatment could ameliorate changes of renal pathology and delay the progression of DKD by suppressing hyperglycemia-induced oxidative stress in diabetic db/db mice.